Motus GI (MOTS) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock MOTS vs. NMRD, UTRS, VIVE, DRTSW, ANZUW, ATAKW, BBLGW, HSCSW, BEATW, and LUCYWShould you be buying Motus GI stock or one of its competitors? The main competitors of Motus GI include Nemaura Medical (NMRD), Minerva Surgical (UTRS), Viveve Medical (VIVE), Alpha Tau Medical (DRTSW), Anzu Special Acquisition Corp I (ANZUW), Aurora Technology Acquisition (ATAKW), Bone Biologics (BBLGW), Heart Test Laboratories (HSCSW), HeartBeam (BEATW), and Innovative Eyewear (LUCYW). These companies are all part of the "medical equipment" industry. Motus GI vs. Its Competitors Nemaura Medical Minerva Surgical Viveve Medical Alpha Tau Medical Anzu Special Acquisition Corp I Aurora Technology Acquisition Bone Biologics Heart Test Laboratories HeartBeam Innovative Eyewear Motus GI (NASDAQ:MOTS) and Nemaura Medical (NASDAQ:NMRD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations. Is MOTS or NMRD more profitable? Company Net Margins Return on Equity Return on Assets Motus GIN/A N/A N/A Nemaura Medical N/A N/A N/A Does the media refer more to MOTS or NMRD? In the previous week, Motus GI's average media sentiment score of 0.00 equaled Nemaura Medical'saverage media sentiment score. Company Overall Sentiment Motus GI Neutral Nemaura Medical Neutral Do institutionals and insiders hold more shares of MOTS or NMRD? 20.1% of Motus GI shares are owned by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are owned by institutional investors. 0.3% of Motus GI shares are owned by insiders. Comparatively, 40.4% of Nemaura Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, MOTS or NMRD? Motus GI has higher revenue and earnings than Nemaura Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMotus GI$319K0.00-$12.87M-$15.64N/ANemaura Medical$3.02K0.00-$14.14M-$0.39N/A Which has more volatility & risk, MOTS or NMRD? Motus GI has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. SummaryMotus GI beats Nemaura Medical on 5 of the 7 factors compared between the two stocks. Get Motus GI News Delivered to You Automatically Sign up to receive the latest news and ratings for MOTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOTS vs. The Competition Export to ExcelMetricMotus GISurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$80.09M$5.76B$9.65BDividend YieldN/AN/A3.91%4.09%P/E Ratio0.0010.9830.7825.12Price / SalesN/A101.45456.64116.46Price / CashN/A18.4125.2228.45Price / BookN/A7.419.375.95Net Income-$12.87M-$26.48M$3.26B$265.46M Motus GI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MOTSMotus GI0.1135 of 5 starsN/AN/AN/A$1K$319K0.0030NMRDNemaura Medical1.2122 of 5 starsN/AN/A-99.8%$4K$3.02K0.0040UTRSMinerva SurgicalN/AN/AN/AN/A$1K$51.69M0.00160VIVEViveve MedicalN/A$0.00flatN/A-66.7%$1K$6.83M0.0070DRTSWAlpha Tau MedicalN/A$0.30+12.6%N/A+29.5%$0.00N/A0.0080Positive NewsGap UpANZUWAnzu Special Acquisition Corp IN/A$0.04flatN/A-52.2%$0.00N/A0.002ATAKWAurora Technology AcquisitionN/A$0.02+38.6%N/A-56.5%$0.00N/A0.00N/AGap UpBBLGWBone BiologicsN/A$10.79-28.1%N/AN/A$0.00N/A0.002Gap DownHSCSWHeart Test LaboratoriesN/A$0.15+36.4%N/A+376.7%$0.00$4.35K0.0010Gap UpBEATWHeartBeamN/A$0.23-27.1%N/A-31.7%$0.00N/A0.005Gap UpLUCYWInnovative EyewearN/A$0.08-0.1%N/A+123.3%$0.00$1.71M0.009 Related Companies and Tools Related Companies NMRD Alternatives UTRS Alternatives VIVE Alternatives DRTSW Alternatives ANZUW Alternatives ATAKW Alternatives BBLGW Alternatives HSCSW Alternatives BEATW Alternatives LUCYW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOTS) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Motus GI Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Motus GI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access